Overview
- The MEOW-1 study has started dosing, with plans to enroll at least 50 obese cats and to monitor outcomes over 12 weeks with an optional 12-week extension.
- About two thirds of participants will receive the implant, which is placed under the skin and steadily releases a GLP-1 agonist for up to six months.
- Investigators aim to assess safety, tolerability, and weight-loss efficacy, with initial results expected next summer.
- Early lab work and a small proof-of-concept in healthy cats suggested weight loss, but effectiveness and broader safety in obese pets remain unproven.
- OKAVA plans a larger study next summer and is targeting FDA approval in 2027–2028, with a stated pricing goal near $100 per month and future testing in dogs and other indications.